SOURCES SOUGHT
65 -- LANCE® Ultra kinase assay kit
- Notice Date
- 2/12/2018
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800062
- Archive Date
- 3/6/2018
- Point of Contact
- Mark E. McNally, Phone: 301-827-5869, Jeffrey Schmidt, Phone: (301) 402-1488
- E-Mail Address
-
mark.mcnally@nih.gov, schmidtjr@mail.nih.gov
(mark.mcnally@nih.gov, schmidtjr@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. Please note that to qualify as an eligible small business for purposes of a small business set-aside, at least 50% of the cost of contract performance incurred for personnel must be expended for employees of the small business awardee (see FAR 52.219-14 Limitations on Subcontracting). This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background : The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) focuses on getting more treatments to more patients more quickly. Several thousand genetic diseases affect humans, of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. The Therapeutics for Rare and Neglected Diseases (TRND) biology program's mission is to encourage and speed the development of new treatments for diseases with high-unmet medical needs. One of the on-going projects in TRND is the Malaria Williamson project that is focused on developing drug candidates to block malaria transmission. The project requires a biochemical assay to counter screen a protein kinase called mammalian target of rapamycin (mTOR), which is an evolutionarily conserved protein kinase implicated in a wide array of cellular processes such as cell growth, proliferation, and survival. The goal of the screening of mTOR activity is to exclude any compounds that could be harmful to human mTOR. This requisition is to acquire the PerkinElmer brand LANCE® Ultra kinase assay kit, consisting of a peptide and an antibody, to continue our efforts of developing an alternate kinase assay in the Malaria Williamson project. This is a brand name-only requirement. This brand-name assay kit is needed to ensure continuity, consistency, and accuracy of test and experiment results with prior tests and experiments conducted using this brand-name assay kit. The LANCE® Ultra kinase assay has been used in a different project the TRND program is working on and will ensure results consistent with that of previous KinEASE assays in the TRND program. Purchase Description : Item 1.) ULight-p70S6K Peptide, PerkinElmer Catalog #TRF0126-M Item 2.) Europium-anti-p-p70S6K (Thr389) Antibody, PerkinElmer Catalog #TRF0214-M Quantity : One (1) assay kit containing six (6) peptides 5nmoles/each and six (6) antibodies 100ug/each. Delivery Date : One (1) time delivery within thirty (30) days after receipt of order. Capability Statement : Contractors believed to possess the ability to provide the required equipment should submit documentation on their ability to meet the purchase description and salient characteristics to the Contract Specialist. The information submitted must be in an outline format addressing each element of the purchase description and all salient characteristics listed in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. All capability statements must provide the following: (1) DUNS number; (2) organization name; (3) organization address; (4) point of contact; (5) point of contact title, address, telephone, and email address; (6) size and type of business (e.g., 8(a), HUBZone, etc.) pursuant to the applicable NAICS code; (7) documentation of ability to provide the required equipment; and, (8) if applicable, any contractor GSA Schedule contracts by which all of the requirements may be met. When submitting this information please reference the solicitation number. Submission Instructions and Due Date : Written capability statements must be SUBMITTED ELECTRONICALLY NO LATER THAN 12:00 P.M. EASTERN STANDARD TIME (EST), MONDAY, FEBRUARY 19, 2018, to Jeffrey Schmidt, Contracting Officer at jeffrey.schmidt@nih.gov with Mark McNally, Contract Specialist cc'd at mark.mcnally@nih.gov. Disclaimer and Important Notes : This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality : No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800062/listing.html)
- Record
- SN04819672-W 20180214/180212231240-9e3fed241607146ffc4cec82b77b41b5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |